×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
DRRX – durect corporation (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
DRRX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/21
02:13 am
drrx
DURECT Co. (NASDAQ: DRRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
DURECT Co. (NASDAQ: DRRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
12/13
02:06 am
drrx
DURECT Co. (NASDAQ: DRRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
DURECT Co. (NASDAQ: DRRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
12/5
02:01 am
drrx
DURECT Co. (NASDAQ: DRRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
DURECT Co. (NASDAQ: DRRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
11/28
11:38 am
drrx
Is BellRing Brands (BRBR) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]
Medium
Report
Is BellRing Brands (BRBR) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]
11/27
03:01 am
drrx
DURECT Co. (NASDAQ: DRRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
DURECT Co. (NASDAQ: DRRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
11/25
06:14 am
drrx
Branford Castle-Backed Lafayette Instrument Acquires Alzet Osmotic Pumps [Yahoo! Finance]
Medium
Report
Branford Castle-Backed Lafayette Instrument Acquires Alzet Osmotic Pumps [Yahoo! Finance]
11/25
06:04 am
drrx
DURECT Corporation Announces Sale of ALZET® Product Line to Lafayette Instrument Co. for $17.5 Million [Yahoo! Finance]
High
Report
DURECT Corporation Announces Sale of ALZET® Product Line to Lafayette Instrument Co. for $17.5 Million [Yahoo! Finance]
11/25
06:00 am
drrx
DURECT Corporation Announces Sale of ALZET® Product Line to Lafayette Instrument Co. for $17.5 Million
Medium
Report
DURECT Corporation Announces Sale of ALZET® Product Line to Lafayette Instrument Co. for $17.5 Million
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/29
02:30 pm
drrx
Form 8-K/A DURECT CORP For: Nov 22
Neutral
Report
Form 8-K/A DURECT CORP For: Nov 22
11/25
09:05 am
drrx
Form 8-K DURECT CORP For: Nov 22
High
Report
Form 8-K DURECT CORP For: Nov 22
11/19
05:10 pm
drrx
Form SC 13G/A DURECT CORP Filed by: ASEN R SCOTT
Medium
Report
Form SC 13G/A DURECT CORP Filed by: ASEN R SCOTT
11/14
04:03 pm
drrx
Form 10-Q DURECT CORP For: Sep 30
Medium
Report
Form 10-Q DURECT CORP For: Sep 30
11/13
04:15 pm
drrx
Form 8-K DURECT CORP For: Nov 13
Medium
Report
Form 8-K DURECT CORP For: Nov 13
10/16
04:47 pm
drrx
Form 4 DURECT CORP For: Oct 14 Filed by: Sussman Norman
Low
Report
Form 4 DURECT CORP For: Oct 14 Filed by: Sussman Norman
10/16
04:46 pm
drrx
Form 4 DURECT CORP For: Oct 14 Filed by: Papp Timothy M.
Low
Report
Form 4 DURECT CORP For: Oct 14 Filed by: Papp Timothy M.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
5/7
DURECT Corporation Announces Preliminary Data from the Ongoing DUR-928 Alcoholic Hepatitis Phase 2a Trial
23.8%
12/21 DURECT Co. (NASDAQ: DRRX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 21.2%
8/1 Form 8-K DURECT CORP For: Aug 01 19.0%
1/17 Biopharma Durect says FDA committee ended meeting with split vote on post-surgical pain treatment [MarketWatch] 16.7%
6/20 DURECT Announces $15 Million Registered Direct Offering 16.7%
3/3 Q4/2019 12/31/2019 EPS -0.020 ZacksConsensus -0.010 ActVsEst (0.010) - Miss 12.8%
6/18 DURECT Announces Completion of the 90 mg Severe Cohort and Dose Escalation Committee Approval to Commence 150 mg Dosing in Patients with Severe Alcoholic Hepatitis (AH) in its Ongoing DUR-928 Phase 2a AH Trial 10.2%
3/5 Novartis Price Fixing, And Other News: The Good, Bad And Ugly Of Biopharma [Seeking Alpha] 8.5%
10/2 DURECT Announces FDA Advisory Committee Meeting to Review POSIMIR® for the Treatment of Post-Surgical Pain 7.1%
12/30 3 Healthcare Stocks With Huge FDA Decisions in January [Yahoo! Finance News] 6.3%
12/21 DURECT Co. (NASDAQ: DRRX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 21.2%
8/1 Form 8-K DURECT CORP For: Aug 01 19.0%
1/17 Biopharma Durect says FDA committee ended meeting with split vote on post-surgical pain treatment [MarketWatch] 16.7%
6/20 DURECT Announces $15 Million Registered Direct Offering 16.7%
3/3 Q4/2019 12/31/2019 EPS -0.020 ZacksConsensus -0.010 ActVsEst (0.010) - Miss 12.8%
6/18 DURECT Announces Completion of the 90 mg Severe Cohort and Dose Escalation Committee Approval to Commence 150 mg Dosing in Patients with Severe Alcoholic Hepatitis (AH) in its Ongoing DUR-928 Phase 2a AH Trial 10.2%
3/5 Novartis Price Fixing, And Other News: The Good, Bad And Ugly Of Biopharma [Seeking Alpha] 8.5%
10/2 DURECT Announces FDA Advisory Committee Meeting to Review POSIMIR® for the Treatment of Post-Surgical Pain 7.1%
12/30 3 Healthcare Stocks With Huge FDA Decisions in January [Yahoo! Finance News] 6.3%
TOP News Decliners
1/2
DURECT Corporation Announces Top-Line Results from Phase 2a Clinical Trial in Patients with Psoriasis
-35.3%
6/27 DURECT Announces Submission to FDA of a Full Response to the POSIMIR® Complete Response Letter -22.8%
7/22 DURECT and Gilead Enter into License Agreement for Long-Acting Injectable HIV Investigational Product -19.1%
7/17 Form 8-K DURECT CORP For: Jul 17 -8.5%
3/7 Edited Transcript of DRRX earnings conference call or presentation 3-Mar-20 9:30pm GMT [Yahoo! Finance News] -8.0%
5/3 Form 8-K DURECT CORP For: May 03 -7.6%
9/27 DURECT (DRRX) Investor Presentation - Slideshow [Seeking Alpha] -7.1%
11/12 DURECT Corporation Announces Positive Results from the Phase 2a Clinical Trial of DUR-928 in Alcoholic Hepatitis Patients in a Late-Breaking Presentation at The Liver Meeting® -7.0%
5/9 DURECT Co. (NASDAQ: DRRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.50 price target on the stock. -6.9%
4/15 DURECT Co. (NASDAQ: DRRX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -6.7%
6/27 DURECT Announces Submission to FDA of a Full Response to the POSIMIR® Complete Response Letter -22.8%
7/22 DURECT and Gilead Enter into License Agreement for Long-Acting Injectable HIV Investigational Product -19.1%
7/17 Form 8-K DURECT CORP For: Jul 17 -8.5%
3/7 Edited Transcript of DRRX earnings conference call or presentation 3-Mar-20 9:30pm GMT [Yahoo! Finance News] -8.0%
5/3 Form 8-K DURECT CORP For: May 03 -7.6%
9/27 DURECT (DRRX) Investor Presentation - Slideshow [Seeking Alpha] -7.1%
11/12 DURECT Corporation Announces Positive Results from the Phase 2a Clinical Trial of DUR-928 in Alcoholic Hepatitis Patients in a Late-Breaking Presentation at The Liver Meeting® -7.0%
5/9 DURECT Co. (NASDAQ: DRRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.50 price target on the stock. -6.9%
4/15 DURECT Co. (NASDAQ: DRRX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -6.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: